Effect of systemic infection induced by Pseudomonas aeruginosa on the brain uptake of colistin in mice

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 10, 2012, Pages 5240-5246

  Jin, Liang ^a   Li, Jian ^a   Nation, Roger L ^a   Nicolazzo, Joseph A ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; CARBON 14; COLISTIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BACTEREMIA; BACTERIAL LOAD; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DRUG UPTAKE; MALE; MOUSE; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; SALMONELLA ENTERICA;

ANIMALS; BACTEREMIA; BLOOD-BRAIN BARRIER; BRAIN; COLISTIN; CYTOKINES; LIPOPOLYSACCHARIDES; MALE; MICE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 84866321632     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00713-12     Document Type: Article

References (41)

1. Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ. 2010. Structure and function of the blood-brain barrier. Neurobiol Dis. 37: 13-25.
2. Abraham CS, Deli MA, Joo F, Megyeri P, Torpier G. 1996. Intracarotid tumor necrosis factor-alpha administration increases the blood-brain barrier permeability in cerebral cortex of the newborn pig: quantitative aspects of double-labelling studies and confocal laser scanning analysis. Neurosci. Lett. 208:85-88.
3. Antachopoulos C, et al. 2010. Serum and cerebrospinal fluid levels of colistin in pediatric patients. Antimicrob. Agents Chemother. 54:3985-3987.
4. Bailer AJ. 1988. Testing for the equality of area under the curves when using destructive measurement techniques. J. Pharmacokinet. Biopharm. 16:303-309.
5. Bergen PJ, Li J, Rayner CR, Nation RL. 2006. Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 50:1953-1958. (Pubitemid 43807511)
6. Beringer P. 2001. The clinical use of colistin in patients with cystic fibrosis. Curr. Opin. Pulm. Med. 7:434-440. (Pubitemid 33065550)
7. Capaldo CT, Nusrat A. 2009. Cytokine regulation of tight junctions. Biochim. Biophys. Acta 1788:864-871.
8. Coisne C, Engelhardt B. 2011. Tight junctions in brain barriers during central nervous system inflammation. Antioxid. Redox Signal. 15:1285-1303.
9. Daley JM, Ivanenko-Johnston T, Reichner JS, Albina JE. 2005. Transcriptional regulation of TNF-alpha production in neutropenia. Am. J. Physiol. Regul. Integr. Comp. Physiol. 288:R409-R412. (Pubitemid 40129606)
10. Deli MA, et al. 1995. Exposure of tumor necrosis factor-alpha to luminal membrane of bovine brain capillary endothelial cells cocultured with astrocytes induces a delayed increase of permeability and cytoplasmic stress fiber formation of actin. J. Neurosci. Res. 41:717-726.
11. Desai TR, Leeper NJ, Hynes KL, Gewertz BL. 2002. Interleukin-6 causes endothelial barrier dysfunction via the protein kinase C pathway. J. Surg. Res. 104:118-123.
12. de Vries HE, et al. 1996. The influence of cytokines on the integrity of the blood-brain barrier in vitro. J. Neuroimmunol. 64:37-43.
13. Dudhani RV, et al. 2010. Elucidation of the pharmacokinetic/ pharmacodynamic determinant of colistin activity against Pseudomonasaeruginosa in murine thigh and lung infection models. Antimicrob. Agents Chemother. 54:1117-1124.
14. Farkas G, et al. 1998. Experimental acute pancreatitis results in increased blood-brain barrier permeability in the rat: a potential role for tumor necrosis factor and interleukin 6. Neurosci. Lett. 242:147-150. (Pubitemid 28275517)
15. Giacometti A, Cirioni O, Barchiesi F, Fortuna M, Scalise G. 1999. In-vitro activity of cationic peptides alone and in combination with clinically used antimicrobial agents against Pseudomonas aeruginosa. J. Antimicrob. Chemother. 44:641-645. (Pubitemid 29532842)
16. He F, et al. 2011. RhoA and NF-kappaB are involved in lipopolysaccharide-induced brain microvascular cell line hyperpermeability. Neuroscience 188:35-47.
17. Jiménez-Mejías ME, et al. 2002. Cerebrospinal fluid penetration and pharmacokinetic/pharmacodynamic parameters of intravenously administered colistin in a case of multidrug-resistant Acinetobacter baumannii meningitis. Eur. J. Clin. Microbiol. Infect. Dis. 21:212-214.
18. Jin L, Li J, Nation RL, Nicolazzo JA. 2009. Brain penetration of colistin in mice assessed by a novel high-performance liquid chromatographic technique. Antimicrob. Agents Chemother. 53:4247-4251.
19. Jin L, Li J, Nation RL, Nicolazzo JA. 2011. Impact of p-glycoprotein inhibition and lipopolysaccharide administration on blood-brain barrier transport of colistin in mice. Antimicrob. Agents Chemother. 55:502-507.
20. Jong A, Huang SH. 2005. Blood-brain barrier drug discovery for central nervous system infections. Curr. Drug Targets Infect. Disord. 5:65-72. (Pubitemid 40467701)
21. Leib SL, Leppert D, Clements J, Tauber MG. 2000. Matrix metalloproteinases contribute to brain damage in experimental pneumococcal meningitis. Infect. Immun. 68:615-620. (Pubitemid 30056514)
22. Li J, Milne RW, Nation RL, Turnidge JD, Coulthard K. 2003. Stability of colistin and colistin methanesulfonate in aqueous media and plasma as determined by high-performance liquid chromatography. Antimicrob. Agents Chemother. 47:1364-1370. (Pubitemid 36368598)
23. Li J, et al. 2004. Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate. J. Antimicrob. Chemother. 53:837-840. (Pubitemid 38660288)
24. Li J, et al. 2006. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect. Dis. 6:589-601.
25. Markantonis SL, et al. 2009. Penetration of colistin into cerebrospinal fluid. Antimicrob. Agents Chemother. 53:4907-4910.
26. Markou N, et al. 2003. Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients. Crit. Care. 7:R78-R83.
27. Mastoraki A, et al. 2008. Pseudomonas aeruginosa susceptible only to colistin in intensive care unit patients. Surg. Infect. (Larchmt.) 9:153-160. (Pubitemid 351563818)
28. Michalopoulos A, Falagas ME. 2008. Colistin and polymyxin B in critical care. Crit. Care Clin. 24:377-391. (Pubitemid 351400615)
29. Michalopoulos AS, Tsiodras S, Rellos K, Mentzelopoulos S, Falagas ME. 2005. Colistin treatment in patients with ICU-acquired infections caused by multiresistant Gram-negative bacteria: the renaissance of an old antibiotic. Clin. Microbiol. Infect. 11:115-121. (Pubitemid 40259694)
30. Morgan L, et al. 2007. Inflammation and dephosphorylation of the tight junction protein occludin in an experimental model of multiple sclerosis. Neuroscience 147:664-673. (Pubitemid 46990645)
31. Nation RL, Li J. 2009. Colistin in the 21st century. Curr. Opin. Infect. Dis. 22:535-543.
32. Oshima T, et al. 2001. Interferon-gamma and interleukin-10 reciprocally regulate endothelial junction integrity and barrier function. Microvasc. Res. 61:130-143. (Pubitemid 32977762)
33. Pajouhesh H, Lenz GR. 2005. Medicinal chemical properties of successful central nervous system drugs. NeuroRx 2:541-553. (Pubitemid 41393264)
34. Reed MD, Stern RC, O'Riordan MA, Blumer JL. 2001. The pharmacokinetics of colistin in patients with cystic fibrosis. J. Clin. Pharmacol. 41: 645-654. (Pubitemid 32493359)
35. Ryge TS, Frimodt-Moller N, Hansen PR. 2008. Antimicrobial activities of twenty lysine-peptoid hybrids against clinically relevant bacteria and fungi. Chemotherapy 54:152-156. (Pubitemid 351448603)
36. Saija A, et al. 1995. Systemic cytokine administration can affect blood-brain barrier permeability in the rat. Life Sci. 56:775-784.
37. Spapen H, Jacobs R, Van Gorp V, Troubleyn J, Honore PM. 2011. Renal and neurological side effects of colistin in critically ill patients. Ann. Intensive Care 1:14-20.
38. Tsao N, Hsu HP, Wu CM, Liu CC, Lei HY. 2001. Tumour necrosis factor-alpha causes an increase in blood-brain barrier permeability during sepsis. J. Med. Microbiol. 50:812-821. (Pubitemid 32802844)
39. Tunkel AR, Rosser SW, Hansen EJ, Scheld WM. 1991. Blood-brain barrier alterations in bacterial meningitis: development of an in vitro model and observations on the effects of lipopolysaccharide. In Vitro Cell. Dev. Biol. 27A:113-120.
40. Vance RE, Hong S, Gronert K, Serhan CN, Mekalanos JJ. 2004. The opportunistic pathogen Pseudomonas aeruginosa carries a secretable arachidonate 15-lipoxygenase. Proc. Natl. Acad. Sci. U. S. A. 101:2135-2139. (Pubitemid 38229027)
41. Wosik K, et al. 2007. Angiotensin II controls occludin function and is required for blood brain barrier maintenance: relevance to multiple sclerosis. J. Neurosci. 27:9032-9042. (Pubitemid 47312066)